PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024

Rhea-AI Summary

PAVmed Inc. to host a business update conference call and webcast to discuss operations, growth strategy, and financial results for the fourth quarter and full year 2023.

Conference Call and Webcast at 8:30 AM Eastern Time

NEW YORK, March 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, March 27, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth-quarter and full year 2023 financial results.

The webcast will be available at the investor relations section of the Company's website at pavmed.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.

About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard^® Esophageal DNA Test and EsoCheck^® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other majority-owned subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.

For more and for more information about PAVmed, please visit pavmed.com.

For more information about Lucid Diagnostics, please visit luciddx.com.

For more information about Veris Health, please visit verishealth.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-to-hold-a-business-update-conference-call-and-webcast-on-march-27-2024-302088057.html

SOURCE PAVmed Inc.

FAQ

When is PAVmed hosting the business update conference call and webcast?

PAVmed is hosting the business update conference call and webcast on Wednesday, March 27, 2024, at 8:30 AM ET.

Who will provide a business update during the call?

Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update.

Who will discuss the financial results for the fourth quarter and full year 2023?

Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the financial results.

How can listeners access the webcast?

Listeners can access the webcast at the investor relations section of the Company's website at pavmed.com.

How can U.S.-based callers access the conference call by telephone?

U.S.-based callers should dial 1-800-836-8184 to access the conference call.

How long will the replay of the conference call be available?

A replay of the conference call will be available for 30 days on the investor relations section of the Company's website at pavmed.com.